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Abstract | Testicular germ cell tumours (GCTs) are the most common malignancy 
occurring in young adult men and the incidence of these tumours is increasing. Current 
research priorities in this field include improving overall survival for patients classified as 
being ‘poor-risk’ and reducing late effects of treatment for patients classified as 
‘goodrisk’. Testicular GCTs are broadly classified into seminomas and nonseminomatous 
GCTs (NSGCTs). The conventional serum protein tumour markers α-fetoprotein (AFP), 
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human chorionic gonadotrophin (HCG) and lactate dehydrogenase (LDH) show some 
utility in the management of testicular malignant GCT. However, AFP and HCG display 
limited sensitivity and specificity, being indicative of yolk sac tumour (AFP) and 
choriocarcinoma or syncytiotrophoblast (HCG) subtypes. Furthermore, LDH is a very 
nonspecific biomarker. Consequently, seminomas and NSGCTs comprising a pure 
embryonal carcinoma subtype are generally negative for these conventional markers. As 
a result, novel universal biomarkers for testicular malignant GCTs are required. 
MicroRNAs are short, non-protein-coding RNAs that show much general promise as 
biomarkers. MicroRNAs from two ‘clusters’, miR-371–373 and miR-302–367, are 
overexpressed in all malignant GCTs, regardless of age (adult or paediatric), site (gonadal 
or extragonadal) and subtype (seminomas, yolk sac tumours or embryonal carcinomas). A 
panel of four circulating microRNAs from these two clusters (miR-371a-3p, miR-372-3p, 
miR-373-3p and miR-367-3p) is highly sensitive and specific for the diagnosis of 
malignant GCT, including seminoma and embryonal carcinoma. In the future, circulating 
microRNAs might be useful in diagnosis, disease monitoring and prognostication of 
testicular malignant GCTs, which might also reduce reliance on serial CT scanning. For 
translation into clinical practice, important practical considerations now need addressing. 
 
Key points 
• The conventional serum protein tumour markers α-fetoprotein (AFP), human 
chorionic gonadotrophin (HCG) and lactate dehydrogenase (LDH) show utility in 
the management of testicular malignant germ cell tumours (GCTs) 
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• AFP and HCG show limited sensitivity and specificity for all malignant GCTs, 
being representative of yolk sac tumour and choriocarcinoma or 
synctiotrophoblast subtypes, respectively; LDH is a very nonspecific biomarker  
• Novel universal biomarkers for testicular malignant GCTs are required, 
particularly for seminoma and embryonal carcinoma subtypes that are typically 
negative for conventional markers 
• MicroRNAs are short, non-protein-coding RNAs that show much promise as 
universal markers in malignant GCTs 
• Individual microRNAs from two microRNA clusters, miR-371–373 and miR-
302–367, are overexpressed in all malignant GCTs, regardless of patient age, 
tumour site and subtype 
• A panel of four circulating microRNAs from these two clusters (miR-371a-3p, 
miR-372-3p, miR-373-3p and miR-367-3p) is highly sensitive and specific for the 
diagnosis of malignant GCT, including seminoma and embryonal carcinoma 
subtypes 
• Practical considerations need to be addressed to standardize the translation of 
circulating microRNA studies from a research tool to a routine clinical test 
 
 
Testicular germ cell tumours (GCTs) are the most common malignancy occurring in 
young adult males and the incidence of these tumours is increasing over time1. Current 
research aims include increasing overall survival for patients deemed to have poor risk 
disease and improving quality of survival for patients with low-stage and/or good-risk 
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disease. Testicular GCTs are broadly classified into seminoma (a malignant subtype) and 
nonseminomatous GCTs (NSGCTs). The latter group include the malignant subtypes 
yolk sac tumour (YST), embryonal and choriocarcinoma (CHC), as well as teratoma. 
Teratomas in prepubertal patients are generally considered benign, but postpubertal cases 
might display malignant potential2. GCTs that contain more than one subtype are known 
as mixed malignant GCTs; those with both seminomatous and nonseminomatous 
components are classified as combined NSGCTs3.  
 
The histological classification and clinical staging of testicular GCTs guide subsequent 
treatment decisions. Stage I testicular GCTs (that is, those confined to the testes) are 
initially treated with orchidectomy, although management after orchidectomy varies and 
can be dictated by clinician and/or national preference4 and/or known risk factors5-10. 
Chemotherapy is routinely administered for patients with stage II–IV testicular GCTs 
according to International Germ Cell Cancer Collaboration (IGCCC) prognostic 
criteria11. 
 
The conventional serum protein biomarkers α-fetoprotein (AFP) and human chorionic 
gonadotropin (HCG) are used to assist in the diagnosis and follow-up assessment of 
GCTs, but their use is generally restricted to tumours containing the relevant malignant 
subtypes YST and CHC, respectively12 (Table 1). Consequently, only ~60% of patients 
with testicular malignant GCTs test positive for these markers at diagnosis13. Serum 
lactate dehydrogenase (LDH) levels are also used at diagnosis to assist with treatment 
decisions in patients with metastatic NSGCTs but this marker lacks sufficient specificity 
5 
 
to be useful in diagnosis or monitoring3 (Table 2). Current priorities in GCT research 
include the identification of universal circulating biomarkers of malignant disease, which 
might assist timely diagnosis and reduce the need for repeated cross-sectional CT 
imaging in follow-up monitoring, along with the associated radiation burden and risk of 
second cancer development14. One recent study, for example, showed that only 3% of 
patients relapsing following a diagnosis of stage I seminoma were identified using 
conventional serum tumour markers (CTMs), but that figure was 87% for CT imaging9. 
Other important issues that remain to be fully addressed include the most appropriate 
management of stage I testicular GCTs, particularly NSGCTs (active surveillance versus 
adjuvant chemotherapy), and the early identification of patients who are destined to have 
poor clinical outcomes within the overall IGCCC poor-risk disease cohort 11. These issues 
are important, as many concerns exist regarding the substantial long-term sequelae of 
conventional chemotherapy treatment15-21, which include pulmonary fibrosis (with 
bleomycin), nephrotoxicity and/or ototoxicity (with cisplatin), neuropathy (with cisplatin 
and taxol agents) 20. Particular concerns also exist about the increased incidence of 
cardiovascular disease17, 18 and second cancer15, 21 associated with conventional 
chemotherapy. Minimizing these risks through improved patient stratification is 
important; novel circulating biomarkers might assist with this challenge. 
This Review provides a comprehensive overview of the current clinical value of serum 
diagnostic testing for testicular GCTs and discusses how the issues highlighted above 
could be addressed. It covers the utility of the traditional markers AFP, HCG and LDH in 
the diagnostic and prognostic management of this disease. In addition, it provides insights 
into the rapidly developing area of quantification of specific circulating short non-
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protein-coding RNAs termed microRNAs in GCTs, and discusses potential clinical 
applications of these markers. Practical aspects that must be considered before such 
microRNA testing can be incorporated into future routine clinical practice are also 
highlighted. The ultimate aims of developing circulating microRNA testing alongside 
conventional tumour marker testing are threefold. Firstly, to rationally reduce or omit the 
use of CT scans in follow-up for patients whose disease is usually negative for 
conventional markers (predominantly seminoma subtype) at diagnosis. Secondly, to 
improve quality of patient survival, through the rational reduction and/or omission of 
chemotherapy, along with its concomitant late effects, for patients with stage I disease, 
who are predicted to have excellent outcomes. Thirdly, to improve overall survival for 
those patients with poor-risk disease, through identification of a robust prognostic 
signature. 
 
[H1] AFP, HCG and LDH in testicular GCT  
The serum protein markers AFP, HCG and LDH have all shown utility for the 
management of testicular GCTs and are currently widely used in clinical practice3.  
 
[H2] Physiology, background and limitations  
AFP is a glycoprotein comprising a carbohydrate moiety attached to an ~600 amino acid 
α-globulin molecule22. In fetal development, AFP is produced by the yolk sac and then 
predominantly the liver, with a minor contribution from the gastrointestinal tract in later 
gestation.23 Postnatally, AFP is gradually replaced as the major circulating protein by 
albumin, which is exclusively derived from the liver22. In clinical practice, AFP levels are 
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determined using a quantitative automated chemiluminescent sandwich enzyme 
immunoassay 24, and measured against known AFP standards according to WHO 
International Standard 72/225 22. The half-life of AFP in the bloodstream is usually ~5–7 
days 3, 22, 25 and levels are measured as ng/ml or kU/l, with normal values being 
<12 ng/ml (<10 kU/l; conversion 1 ng/ml = 0.84 kU/l) 22. The features of AFP production 
during development are pertinent to the elevations observed in the serum of some patients 
with GCTs. Raised serum AFP levels are predominantly observed in GCTs containing 
YST components, although moderately elevated values can also occur in some embryonal 
carcinoma and immature teratoma lesions 22 (Table 1). In pure immature teratoma, serum 
AFP can be raised owing to the presence of immature liver and/or gastrointestinal tissues 
within the lesion22. 
AFP values are typically elevated in patients with hepatocellular carcinoma3, in patients 
with other uncomplicated chronic liver disease,26 those who have undergone 
gastrointestinal tract and/or hepatic surgery and in patients with certain conditions such as 
hereditary ataxia telangiectasia27. Infrequent reports of elevated AFP levels have also 
been described in gastrointestinal malignancies3, 22 (including gastric, pancreatic and 
colon carcinoma), which have the potential for AFP production to be de-repressed, as 
well as in carcinoma of the lung 3. Interestingly, patients with GCTs have been reported 
to have false elevations of AFP, secondary to liver damage caused by chemotherapy, 
anaesthetic agents or other drugs.28 Without awareness of such possibilities, patient 
management could potentially be altered based on such results. Thus, interpretation of 
AFP levels should only be undertaken with full knowledge of the patient’s history and 
examination findings, including age, symptoms, past medical and family history and any 
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relevant drug history 22. In patients in whom potential liver disease is a concern, a full 
serum liver function test should be performed alongside AFP estimation 22. 
 
HCG measurements can be of the free ß-subunit alone (monomer), the α–ß dimer (‘intact 
HCG’), or both (‘total HCG’, often referred to as ‘ß-HCG’) 3. HCG is measured with a 
double antibody immunometric assay 3, typically using lanthanide fluorescence. Normal 
HCG levels are <2 IU/l, although levels can be measured in ng/ml (where 
5 IU/l = 1 ng/ml). The half-life of HCG is much shorter than AFP, usually ~12–36 h 3, 29, 
and, therefore, levels should decay much more rapidly. HCG is produced primarily by 
CHC components, but low levels of HCG production can be observed in patients with 
pure seminoma containing syncytiotrophoblast (placental-like) cells (Table 1). However, 
even patients with advanced-stage pure seminoma only show raised HCG values in <20% 
of cases 3. HCG, like AFP, also shows limitations in sensitivity and specificity. Levels 
can also be elevated in other malignancies, including neuroendocrine, bladder, renal and 
lung carcinomas 3. The treating clinician needs to be aware of the limited sensitivity of 
both HCG and AFP to ensure appropriate patient management. 
 
LDH is an enzyme that catalyses the conversion of lactate to pyruvate3 and is 
ubiquitously expressed in cells of the body. Elevations in LDH are therefore very 
nonspecific, but can indicate increased cell turnover, such as in malignancy, including 
testicular GCTs. The half-life of LDH in the bloodstream is not well reported as serial 
measurements are not usually taken, but is measured in days rather than hours. An 
enzymatic assay measures circulating levels, but assays used between laboratories are 
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very variable. LDH is often routinely measured at the time of cancer diagnosis, providing 
a surrogate measure for tumour bulk, and high levels are associated with an increased risk 
of tumour lysis syndrome, which can occur in patients with malignant GCTs 30. Increased 
levels are also observed in lymphoma, lung cancer and bone tumours such as 
osteosarcoma and Ewing sarcoma, as well as in any non-malignant condition that results 
in cellular lysis or injury, such as such as myocardial infarction or liver or muscle damage 
or disease 3. These variations limit the use of LDH as a biomarker. 
 
[H2] Diagnosis and early follow-up monitoring  
[H3] Preorchidectomy. Measurement of CTM levels before orchidectomy is advised in 
all cases, as a substantially elevated preoperative AFP level precludes a diagnosis of pure 
seminoma, regardless of histological findings, and, in addition, this approach assists the 
interpretation of postorchidectomy estimations 3. Furthermore, in rare cases, such as 
testicular GCTs with considerable tumour burden where urgent treatment is required, or 
extragonadal cases (such as retroperitoneal or mediastinal primary), in which the risks of 
surgical biopsy are deemed excessive, a substantially raised AFP and/or HCG might be 
sufficient for diagnosis 3.  
 
[H3] Stage I disease. Stage I testicular GCT is defined by the absence of demonstrable 
disease elsewhere on radiological imaging (that is, the disease is confined to the testis) 
and either normal levels of AFP and HCG, or if these levels were raised preoperatively, 
normalization following surgery. However, a proportion of patients with stage I 
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malignant GCTs will develop clinical relapse during follow-up monitoring, and therefore 
for some patients, postorchidectomy risk stratification is undertaken.  
 
Patients with NSGCTs are one such group whererisk stratification is usually undertaken; 
those at low risk of subsequent relapse are monitored with surveillance and patients with 
high-risk disease might be offered adjuvant therapy rather than surveillance. Effective 
adjuvant treatments that substantially reduce relapse risk in this setting include single-
dose carboplatin or radiotherapy for stage I seminoma and one course of bleomycin, 
etoposide and cisplatin (BEP) chemotherapy for stage I NSGCT 4. The most important 
and consistently reported risk factors for recurrence in patients with stage I NSGCT has 
been the presence of lymphovascular invasion (LVI)5-7, 9, 10. Patients without LVI have a 
predicted 15–20% risk of recurrence; in those with LVI, this risk is 40–50%. The 
percentage embryonal carcinoma in the resection specimen (%EC) 6, 7, 10 and rete testis 
invasion (RTI) 6 have also been reported to affect recurrence rates. In one large study of 
more than 1,000 patients, the overall relapse risk at 5 years after orchidectomy was 12% 
with none of these risk factors, compared with 50% with all three of these risk factors 
(31% for the cohort as a whole) 6. A further study demonstrated that 
immunohistochemical expression of CXCL12 [also known as stromal cell-derived factor 
1 (SDF1)], in stage I NSGCTs was associated with reduced relapse risk31, a finding that 
has now been independently validated and shown to offer additional risk stratification 
benefit over LVI alone7. The authors propose a new prognostic index using CXCL12 
expression in addition to LVI and %EC, with three proposed risk groups (low, with a 
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~10% relapse risk; moderate, with a ~30–40% relapse risk; and high, with a ~70% 
relapse risk) 7, although this index remains to be prospectively validated in a trial setting. 
 
Risk stratification of patients with seminoma has been more controversial than for those 
with NSGCTs. A review of 638 patients identified tumour size, RTI and LVI as being 
risk factors for relapse on univariate analysis with tumour size and RTI remaining as risk 
factors on multivariate analysis32. A risk of relapse of 12%, 15% and 31% was identified 
if zero, one or two risk factors were present, respectively 32. This prognostic index has 
never been fully validated and indeed, in an analysis of data from 685 patients with stage 
I seminoma, only tumour size was a significant risk factor for relapse33. Risk of relapse 
increased from 9% for a 1 cm diameter tumour to 26% for an 8 cm diameter tumour 33. 
Accurate prediction of relapse risk in this patient group remains elusive. 
 
Novel circulating biomarkers could offer considerable additional value and refinement to 
such stratification systems in patients with stage I disease. For instance, a marker that 
shows increased sensitivity for residual microscopic disease might substantially reduce 
the need for adjuvant therapy. 
 
[H3] Metastatic disease. Chemotherapy is routinely administered to patients with stage 
II–IV testicular GCTs according to IGCCC prognostic criteria 11 (Table 2). Current 
standard-of-care treatment is three courses of BEP chemotherapy or four cycles of 
etoposide and cisplatin (EP) for good-risk disease (60% of patients; 91% 5-year overall 
survival) and four BEP cycles for intermediate-risk disease (26% of patients; 79% overall 
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survival) and high-risk disease (14% of patients; 48% overall survival) patients11. By 
IGCCC definition, patients with pure seminoma have normal levels of AFP. In the pooled 
multivariate analysis however, LDH levels of more than double the institutional upper 
limit of normal (ULN) in the metastatic seminoma cohort were predictive of shorter 
progression-free survival (PFS) and overall survival, but the IGCCC classification 
successfully stratified patients into intermediate-risk (10% of patients) and good-risk 
groups (90% of patients) solely by the presence or absence of nonpulmonary visceral 
metastases, respectively11. Thus, in patients with metastatic seminoma, the level of LDH 
and HCG does not affect their prognosis or treatment11. For those with NSGCT, however, 
AFP, HCG and LDH all have a role in determining IGCCC risk group (Table 2) 11. The 
good-risk NSGCT group comprises patients with diagnostic serum levels of AFP 
<1,000 ng/ml, HCG <5,000 IU/l and LDH <1.5 times the ULN 11. The intermediate-
group values are AFP >1,000 but ≤10,000 ng/ml, HCG >5,000 but ≤50,000 IU/l or LDH 
>1.5 times but ≤10 times the ULN. Finally, the poor-risk group comprises those patients 
with any CTM values above the upper limit of the intermediate-risk group range, plus 
patients with a mediastinal primary and/or nonpulmonary visceral metastases (Table 2) 11. 
For patients who are AFP-positive and/or HCG-positive at diagnosis, measurement of 
AFP and/or HCG levels is recommended at the start of each chemotherapy cycle, in order 
to monitor the effectiveness of treatment. AFP and HCG should be measured at the end 
of treatment in all patients, as ~50% of patients with metastatic seminoma who have an 
elevated HCG after chemotherapy experience subsequent relapse34, 35 and some relapses 
manifest as NSGCTs3. End-of-treatment AFP and HCG levels generally do not assist in 
the identification of patients who could avoid retroperitoneal lymph node dissection or 
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resection of residual tumour masses - surgery should go ahead unless CTMs are 
increasing, in which case a change to alternative chemotherapy is likely to be indicated3. 
 
Measurement of serum AFP levels and/or decline might in the future help to further 
segregate IGCCC cohorts. One study of patients with intermediate-risk disease used AFP 
levels to further separate this population into two groups, with the small percentage of 
patients with values >6,200 ng/ml having an overall survival similar to the IGCCC poor-
risk group, whereas those with values less than this threshold had outcomes that 
approximated to those in the IGCCC good-risk group36. This suggestion remains to be 
validated prospectively. Clinical outcomes remain suboptimal for the ~15% of patients 
with IGCCC poor-risk disease11. A previous attempt to further segregate the poor-risk 
group using the statistical technique of tree modelling was unsuccessful37. Furthermore, 
despite more than three decades of randomized controlled trials of treatment escalation 
(such as the addition of multi-agent chemotherapy38, taxols39, or high-dose therapy40, 
very few studies have demonstrated any clear additional survival benefit for such 
approaches. However, the early rate of decline of serum AFP and HCG levels has been 
shown to be of additional prognostic value in poor-risk patients41. Tumour markers were 
measured just before initiation of chemotherapy and again 3 weeks later (i.e. between 
days 18–21 inclusive), and rate of decline was expressed as predicted time to 
normalization (TTN) 41. The 4-year PFS rates were 44% for the poor-risk group as a 
whole, but 64% and 38% in patients who had a favourable and an unfavourable TTN, 
respectively, independent of initial marker levels, disease site and the presence of non-
pulmonary visceral metastases 41. Early TTN was thus identified as an independent 
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prognostic factor in poor-risk patients41. The prospective multicentre study GETUG13, 
which reported results in 2014, based treatment intensification on this early TTN and 
showed improved 3-year PFS in a randomized comparison of a dose-dense schedule 
versus standard BEP in patients with unfavourable marker decline (59% versus 48%, 
respectively) 42. The 3-year PFS in the small number of patients remaining in the 
favourable marker decline group was 70%42. As a result, the GETUG13 study has been 
suggested to be a practice-changing step in the management of these NSGCTs 43, 44. 
However, some concerns exist with this approach. Firstly, the timing of the reassessment 
of AFP level is strict and the calculation of the rate of decline in clinical practice can be 
challenging. For example, an AFP ‘surge’ or ‘flare’ on day 8 (compared with levels on 
day 1) following initiation of chemotherapy in patients with NSGCTs has been shown to 
be of adverse prognostic significance45, and such a phenomenon does not, therefore, 
simply represent a marker of tumour lysis45. As a result, interpretation of AFP levels at 
the beginning of the second course of chemotherapy in patients displaying an AFP flare 
should be undertaken with appropriate caution3. The effect of early AFP flares on the 
GETUG13 results is not clear. Secondly, the majority of patients (80%) on the GETUG13 
trial displayed unfavourable TTN of tumour markers41, and if these results of dose-dense 
schedules are adopted and replicated prospectively in other studies, most patients will 
receive treatment intensification with the potential for only modest benefit in PFS. 
Thirdly, even the identified ‘good-risk’ group within this poor-risk study had only a 70% 
3-year PFS, suggesting that, even in this cohort, outcomes are suboptimal. Finally, some 
patients in the poor-risk group were successfully treated by BEP alone, suggesting that 
improved prognostication would be valuable. 
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AFP and/or HCG values that show an increase during therapy (aside from an initial surge 
or flare), usually indicate (YST-containing and/or CHC-containing) resistant or refractory 
disease and warrant a change in management3. Novel circulating biomarkers to better 
assist identification of all truly cisplatin-refractory cases upfront, either at the time of 
diagnosis or during early treatment (in both IGCCC intermediate-risk and poor-risk 
cohorts) would therefore be welcomed 20. 
 
[H2] Detection of testicular GCT recurrence 
In patients with stage I testicular GCT disease, active surveillance after orchidectomy has 
been shown to lead to excellent outcomes (5-year disease-specific survival of 99.7%9. 
Close monitoring of such patients not receiving adjuvant chemotherapy is needed, as a 
proportion harbour occult metastases, leading to subsequent relapse7. Approximately 20–
30% of NSGCT and 10–20% of seminoma cases, respectively, relapse in this way6, 7, 9. 
The vast majority (92%) of NSGCT relapses have occurred by 2 years of follow-up 
monitoring 9. Such relapse patterns and frequency guide the intervals for CTM estimation 
during follow-up monitoring. The American Society of Clinical Oncology Clinical 
Practice Guideline recommends that follow-up assessment includes measurement of AFP 
and HCG levels in patients with stage I, chemotherapy-naive NSGCTs3. Markers are 
most commonly measured monthly during the first year of follow-up and every 2 months 
in the second year, with frequency reduced further thereafter3. Following a diagnosis of 
stage I pure seminoma, of those patients who will ultimately experience a relapse, 75% 
will have done so by 2 years and 92% by 3 years9. However, owing to the lack of 
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sensitive markers, evidence for the clinical benefit of CTM estimation during follow-up 
visits is lacking in this population, and, therefore, not recommended 3. For example, a 
2015 study showed that only 3% of stage I seminoma recurrences were detected by CTM 
evaluation, and even for stage I NSGCT cohorts, more than half of all relapses were 
negative by CTM estimation9.  In the latter groups, CTM evaluation was only  positive in 
60% and 41% of stage I NSGCT patients with and without LVI, respectively 9, 
explaining the reliance on 3D imaging in follow-up assessment and the highlighting the 
clinical need for markers of increased sensitivity and specificity for malignant GCT 
disease. 
For patients with metastatic NSGCT after chemotherapy, follow-up measurement of both 
AFP and HCG is recommended, with the same interval and duration of follow-up as for 
stage I disease. For patients with advanced stage seminomas, 40% of whom have elevated 
HCG at diagnosis, follow-up measurement of CTMs is also recommended3. Such follow-
up monitoring is recommended as rising CTM levels can represent the earliest sign of 
malignant GCT recurrence or relapse, before clinical or radiological evidence is present,46 
although most clinicians would wait to see evidence of disease on imaging findings, 
before instigating appropriate management changes. Owing to the lack of direct evidence 
for their clinical benefit (for example, improved overall survival), recommended intervals 
for CTM estimation following treatment of advanced seminoma are generally less 
frequent than for NSGCT, typically every 2 months during the first year of follow-up 
monitoring, every 4 months during the second year, and less frequently thereafter 3. In 
addition, no clear evidence indicates that LDH measurement is useful for the detection of 
recurrence during follow-up of patients with testicular GCT (including those with low-
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stage or advanced-stage, NSGCT or seminoma), owing to its lack of specificity 47, 48, and, 
therefore, such evaluation is not advised 3. 
 
[H1] Other potential markers and investigations  
As AFP, HCG and LDH are not universal markers of malignant GCTs, researchers have 
attempted to identify other potential candidate blood-based biomarkers and investigations 
for GCTs. 
[H2] Circulating XIST transcripts 
Demethylated promoter regions of the long noncoding RNA X inactive specific transcript 
(XIST) gene at Xq13.2 have been reported in the plasma of men with testicular GCTs49. 
However, the 2004 study showing this finding was small, it only demonstrated an overall 
sensitivity of 64% for malignant testicular GCTs49 and the finding has not been 
confirmed by other reports. Thus, XIST promoter demethylation currently lacks the 
sensitivity and specificity required for a clinical test. Consequently, an urgent need 
remains to identify highly sensitive and specific serum markers for all malignant 
testicular GCTs, particularly for the detection of seminoma and embryonal carcinoma 
subtypes, which are predominantly marker-negative by CTM estimation. 
 
[H2] Circulating mRNA transcripts 
No reports have described circulating protein-coding mRNA transcripts as potential 
biomarkers in any malignant GCTs. Translation of any such candidate mRNA biomarker 
into the clinic would also be difficult, as mRNAs display relative instability at room 
temperature and in samples stored suboptimally50, 51. 
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[H2] PET scans 
18F-fluorodeoxyglucose (FDG)–PET scans show better sensitivity and specificity for 
detecting active disease in seminoma masses after chemotherapy than does anatomical 
CT imaging, and consequently has become standard-of-care52, 53. 18FDG–PET might also 
have a role in detecting sites of relapse in patients with rising CTM levels after 
chemotherapy 54. However, despite encouraging pilot data, 18FDG–PET was 
insufficiently sensitive in patients with stage I high-risk LVI-positive NSGCT to identify 
a substantial proportion of patients who subsequently relapsed55. Likewise, this imaging 
modality has not been useful in predicting the histology of residual masses in patients 
with NSGCT treated with surgery. A full description of the role of PET scans in testicular 
GCT is outside the scope of this Review.  
 
[H1] MicroRNAs in diagnosis and monitoring 
The discovery of biological abnormalities that are common to all malignant GCTs is 
clinically relevant. Such abnormalities are likely to be critically important in disease 
pathogenesis, offer potential as biomarkers and might assist the identification of novel 
therapeutic targets in this disease 20. MicroRNAs are short, non-protein-coding RNAs that 
regulate the expression of protein-coding genes. MicroRNAs are dysregulated in cancer, 
but expression profiles retain the characteristics of the cell of origin20. The first report of 
microRNA expression in malignant GCTs showed that the miR-371–373 microRNA 
cluster (at chromosomal location 19q13) was highly expressed in adult testicular disease, 
and might function as a potential oncogene through inhibition of LATS256. Subsequently, 
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the specific overexpression of the miR-371–373 cluster in testicular GCTs was confirmed 
in a study that also included some adult ovarian malignant GCT cases57. These findings 
were then extended in a report demonstrating that the miR-371–373 cluster and, in 
addition, the miR-302–367 cluster (miR-302a-d plus miR-367; at 4q25) were both 
overexpressed in all malignant GCTs, independent of patient age (paediatric or adult), 
tumour histological subtype (YST, seminoma or embryonal carcinoma) or anatomical site 
(gonadal or extragonadal) 58, representing the first universal molecular abnormality 
identified in this disease20. Across >100 clinical cases, the expression levels of the eight 
main microRNA members from the miR-371–373 and miR-302–367 clusters accurately 
separated malignant GCTs from nonmalignant samples, comprising normal gonadal 
control samples and teratomas (Fig 1)58 These findings suggest that microRNAs from the 
miR-371–373 and miR-302–367 clusters are potential highly sensitive and specific 
universal biomarkers of all malignant GCTs20. These observations have now been 
independently confirmed59, including the observation that these microRNA changes occur 
in germ cell neoplasia in situ60, the precursor lesion to testicular GCTs, implying that 
overexpression of these microRNAs represents an early molecular change that is likely to 
have a fundamental role in GCT pathogenesis. Importantly, these microRNAs have not 
been shown to be co-ordinately overexpressed in any other cancer or disease state, adding 
to their biomarker potential58. 
 
MicroRNAs are released into the bloodstream from cancer cells, often contained within 
membrane-bound particles, termed exosomes, and are therefore protected from 
degradation61, 62. Consequently, the quantification of circulating microRNAs offers 
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substantial promise for cancer diagnosis and monitoring63. For malignant GCTs, a 
multiplexed quantitative reverse transcription (qRT)-PCR methodology approach was used 
to demonstrate that circulating levels of all eight main members of the miR-371–373 and 
miR-302–367 clusters were elevated in the serum of an index patient with extragonadal 
disease, compared with levels in pooled normal serum63. Levels of miR-372-3p fell to 
normal levels during treatment and during  uneventful clinical follow-up monitoring63. 
This proof-of-principle was followed by a small study across the clinical spectra of age 
(paediatric and adult), anatomical site [gonadal (including testicular) and extragonadal] and 
histological subtype (YST, seminoma and embryonal carcinoma), confirming universal 
elevation at malignant GCT diagnosis of serum levels of miR-372-3p and miR-367-3p64. 
Importantly, most of the patients described in this study were marker-negative by CTM 
estimation (specifically the seminoma and embryonal carcinoma cases), demonstrating 
potential clinical utility in these cohorts. 
These initial findings have since been replicated and extended, based on the qRT-PCR 
methodology described 12, 13, 64-70, predominantly in malignant testicular GCTs. Indeed, a panel 
of just four circulating microRNAs (namely miR-371a-3p, miR-372-3p, miR-373-3p and miR-
367-3p) is highly sensitive and specific for diagnosis of malignant GCT 12, 66, 70. Circulating 
microRNA levels from the panel fall after definitive surgery and/or chemotherapy treatment12, 
13, 63, 66, 70, and are also highly sensitive for detecting relapse 12. 
 
 
 
[H2] Practical considerations for microRNA testing  
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Circulating microRNAs are now starting to be be studied in prospective clinical trials in 
patients with GCTs, with the ultimate aim of embedding microRNA quantification in 
routine clinical practice. However, at present no agreed protocol exists for sample 
collection, RNA extraction, quality control assessment or actual PCR quantification, and 
indeed, the full panel of four microRNAs that might offer the greatest sensitivity and 
specificity for detecting all malignant testicular GCTs has not always been quantified 
(Table 3). These issues are all important and need to be overcome to ensure optimal 
reliability and reproducibility and to drive these research technologies towards future 
clinical use in testicular GCTs.  
 
[H3] Sample collection.  
To date, all studies specifically reporting circulating microRNA levels from the miR-
371–373 and miR-302–367 clusters in malignant GCTs have used serum 12, 13, 63-70. To 
ensure consistent results, the whole blood collected in these serum separator tubes should 
be centrifuged in a standard fashion within a few hours following receipt, and the 
resultant serum aliquoted into separate tubes for processing, with subsequent storage at –
80oC. The starting serum volumes used for testing have reduced in recent years. Initially, 
400 μl was used63, 64; 200μl is now the most common starting volume, but as little as 
50 μl can be sufficient66, 67 (Table 3). Plasma might also be suitable for testing, as serum 
and plasma microRNA levels are believed to correlate well71, although such a correlation 
remains to be formally demonstrated for the panel of four circulating microRNAs at the 
time of malignant GCT diagnosis. If proven to be suitable, the use of plasma would offer 
the additional benefit of enabling any circulating tumour DNA (ctDNA) that is present to 
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be extracted, which is important as mutational profiles in testicular GCTs using whole-
exome sequencing have now been reported 72. Mutations occurred in 43% of the tumours 
interrogated, with aberrations in the KIT gene (occurring in 14.3% of tumours) being the 
most common. Of particular interest, two treatment-refractory cases were identified, both 
of which harboured XRCC2 mutations, a gene implicated in cisplatin resistance72. 
Collection of plasma in prospective studies might, therefore, offer further opportunities 
for the molecular diagnosis and risk stratification of malignant GCTs. [H3] RNA 
extraction. 
RNA is extracted from serum using commercially available proprietary kits (Table 3). 
The subsequent PCR reactions are also performed using standard TaqMan assay kits and 
platforms (Table 3). To avoid false-positive and false-negative results, no-template 
controls should be run for each assay (to exclude nonspecific amplification) and any 
differences in RNA extraction efficiency between samples measured, so that these 
differences can be accounted for in subsequent data analysis73. The latter is performed by 
adding a fixed quantity of exogenous nonhuman spike-in microRNA(s) (for example, C. 
elegans (cel)-miR-39-3p or A. thaliana (ath)-miR-159-3p), that does not occur naturally 
in human serum, which is then quantified and adjusted for. Not all reported studies use 
such a quality control step (Table 3), despite it providing additional stringency and being 
considered best practice12, as per Minimal Information in Q-PCR Experiment (MIQE) 
guidelines73. MIQE guidelines assist both the transparency of result reporting and the 
comparison of results between different studies, which may facilitate the subsequent 
standardization of protocols73. The selection of endogenous circulating microRNA 
housekeeping genes for data normalization (relative quantification) is also of critical 
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importance, as this step minimizes technical bias and maximizes detection of true 
biological variation between serum samples12. Early studies did not include such 
normalization steps 63, 64, as no stable housekeeping microRNAs had been established. In 
many subsequent reports, no clear rationale is given for the selection of different 
housekeeping genes for this purpose (Table 3). However, one MIQE-compliant 2016 
report has identified miR-30b-5p as being the most stable microRNA in serum, based on 
a global microRNA study (n = 741) and subsequent validation in serum from patients 
with malignant GCTs12. Some researchers suggest that such relative quantification might 
be unnecessary for clinical testing and that raw PCR results provide adequate diagnostic 
discrimination69. However, such an approach may not be optimal when using current 
qRT-PCR methodology to quantify the full panel of four circulating microRNAs that 
offer the greatest accuracy for malignant GCT diagnosis12. The dynamic range for 
circulating miR-372-3p, miR-373-3p and miR-367-3p is lower than for circulating miR-
371a-3p12. Consequently, differences in extraction efficiency will have a relatively high 
impact on overall PCR measurements and, therefore, careful control via relative 
quantification approaches is still recommended12. 
[H3] Haemolysis. 
Haemolysis might also be an important practical consideration in adopting serum 
microRNA tests for routine clinical detection of testicular malignant GCTs, as variations 
in red blood cell lysis between serum and plasma samples might result in altered 
circulating microRNA expression levels for technical, rather than biological, reasons. 
Consequently, a 2016 study only used samples without macroscopic evidence of 
haemolysis, and calculated ΔCt (miR-23a-3p minus miR-451a) values to assess 
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differences in microscopic haemolysis between samples 12 (Table 3). MiR-23a-3p 
quantification is used as a housekeeping gene to enable a ΔCt value to be estimated, and 
miR-451a levels directly reflect the degree of haemolysis of the sample being 
interrogated, as this microRNA is one of the most abundant in red blood cells12. Other 
methods, such as spectrophotometry for quantification of free haemoglobin in the serum, 
can quantify the degree of haemolysis within a sample. The value of such assessments in 
circulating microRNA testing remains to be established for the diagnosis of malignant 
GCT. However, we recommend that a formal method of haemolysis assessment should 
continue to be performed at present, to inform how much contribution haemolysis makes 
to any potential false positive results in future trials of circulating microRNAs in 
malignant GCTs, and to enable appropriate adjustments to be made. 
[H3] Using the full panel of four microRNAs. 
For maximal sensitivity and specificity, using the full panel of four microRNAs from the 
miR-371–373 and miR-302–367 clusters is advisable12, 66, 70. The sensitivity of miR-
371a-3p alone is generally ~90% for the diagnosis of malignant GCT68, but sensitivity 
and specificity can be increased further by using the panel12, 66, 70. For example, the 
particularly rapid reduction in miR-371a-3p levels following orchidectomy in stage I 
disease68 can result in negative results in samples taken more than one day after surgery, 
whereas the other microRNAs in the panel have longer half-lives12. Accordingly, in cases 
in which the timing of the ‘diagnostic’ serum sample is suboptimal (for example, taken 
following surgery), assessment of miR-371a-3p alone might result in (false) negative 
results. Furthermore, assessment of circulating levels of miR-367-3p increases specificity 
for the identification of malignant GCTs, as it is transcribed from a separate chromosome 
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locus (4q25) to the other three microRNAs in the panel (19q13)12. Such assessment is 
important, as although individual microRNAs from either the miR-371–373 or the miR-
302–367 cluster have been shown to be increased in certain malignancies, coordinate 
overexpression of microRNAs from both clusters have not been demonstrated in any 
tumour other than malignant GCTs, or in any other disease state 57. We have proposed a 
pipeline for the quantification of circulating microRNAs in malignant GCTs that 
addresses these issues (Fig 2).  
 
Very recently, two further serum microRNA studies in testicular GCTs have been 
published (refs 73 and 74 – van Agthoven and Looijenga PMID 27487133 and 
Dieckmann et al PMID 27495845). Both showed that the panel of miR-371–373 and 
miR-367-3p microRNAs was significantly elevated in patients with malignant testicular 
GCTs at the time of diagnosis, using the originally described pre-amplification step (ref 
63), which maximises sensitivity of the test. MiR-371a-3p was the most sensitive and 
specific individual microRNA from the serum panel in these analyses, with area under 
the curve (AUC) values of 0.95 and 0.94, respectively (refs 73 and 74 – van Agthoven 
and Looijenga PMID 27487133 and Dieckmann et al PMID 27495845). One study did 
not use an exogenous nonhuman spike-in microRNA and used miR-93-5p for 
normalisation (ref 74 Dieckmann et al). The other used a nonhuman spike-in and selected 
miR-30b-5p as the housekeeping gene (ref 73 van Agthoven and Looijenga), as 
previously described (ref 12). Interestingly, this was because miR-93-5p was found to be 
unsuitable for normalisation due to a significant difference in levels between the 
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malignant GCT group and the control patients (ref 73 van Agthoven and Looijenga). 
Neither study used a formal haemolysis method to assess the samples (Table 3). 
[H3] Cost and the future. 
Currently, as a relatively low-throughput research method using the described pipeline 
(Fig 2)12, circulating microRNA analysis costs approximately UK£40 per sample. This 
figure compares favourably with the cost of a single CT scan of ~£200. In due course, 
when such a method is in routine clinical use with higher throughput, economies of scale 
are likely to reduce these costs further. In the future, robust absolute quantification PCR 
methods might overcome the need for relative quantification when measuring circulating 
microRNA levels, although the requirement to use nonhuman spike-ins or other 
appropriate standards will remain, to ensure the accuracy of RNA extraction steps and 
subsequent PCR quantification within and between samples. Such measures should 
improve sensitivity and specificity overall and provide greater confidence in borderline 
cases, ensuring that clinical decisions are not undermined by subtle technical effects 12. 
[H1] Conclusions  
The conventional tumour markers AFP, HCG and LDH have demonstrated value in the 
clinical management of testicular malignant GCTs, particularly for early risk-
stratification of metastatic NSGCTs and detection of relapse in patients with NSGCT. 
However, their limitations in sensitivity and specificity prevent more universal 
application, especially in patients with seminoma. Circulating microRNAs show exciting 
promise as a universal marker of testicular malignant GCTs. Such biomarkers could 
considerably contribute to improving the quality of survival for patients in low-stage 
and/or IGCCC good-risk groups, through rational reductions in adjuvant chemotherapy, 
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improved targeted imaging and detection of relapse at an earlier stage. Their use might 
also enable new approaches to increase overall survival among IGCCC poor-risk and 
relapsed disease cohorts by modifying treatment and identifying patients who should 
receive intensified treatment. 
As these novel biomarkers are now being studied in prospective clinical trials, the 
practical considerations discussed in this Review should be addressed and incorporated 
into standardized protocols. We suggest that haemolysis assessment, alongside 
normalization to both a nonhuman exogenous spike-in RNA (e.g. cel-miR-39-3p) and 
carefully selected endogenous housekeeping microRNAs (e.g. miR-30b-5p), are optimal 
approaches for the relative quantification PCR methods currently in use. Such robust 
protocols will ensure the optimal reliability and reproducibility of these tests in clinical 
settings. 
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Figure 1 | Differential expression of the microRNAs (miR)-371–373 and miR-302–
367 clusters in malignant germ cell tumours (GCT). Hierarchical clustering analysis 
based on the eight main microRNAs from the miR-371–373 and miR-302–367 clusters 
(rows) segregates a | paediatric and b | adult malignant GCT samples from nonmalignant 
controls (comprising benign teratomas and normal gonadal controls) (columns). In the 
heatmap, red represents relative microRNA overexpression and blue represents 
underexpression. Green columns = normal gonadal controls; brown columns = teratoma; 
blue columns = seminoma; yellow columns = yolk sac tumour; red columns = embryonal 
carcinoma. 
 
Figure 2 | A proposed pipeline for quantification of circulating microRNAs (miRs) 
in malignant germ cell tumours (GCTs)12. At the RNA extraction stage (green box), a 
fixed quantity of the non-human spike-in RNA cel-miR-39-3p is added to enable 
subsequent exogenous normalisation. An initial quality control quantitative reverse 
transcription (qRT)-PCR step is then performed (blue box) to check for satisfactory levels 
of exogenous cel-miR-39-3p (indicating satisfactory RNA extraction), endogenous 
housekeeping microRNA (miR-30b-5p) and for haemolysis assessment. Once a serum 
sample has passed this step, formal microRNA quantification is then performed, using a 
multiplexed reverse transcription and preamplification step (purple box), which includes 
the panel of four test microRNAs (miR-371a-3p, miR-372-3p, miR-373-3p and miR-367-
3p). Data analysis is then undertaken (red box). 
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Table 1 | Serum AFP and HCG levels generally observed in germ cell tumour 
subtypes (adapted from reference22)  
GCT histological subtype AFP HCG 
Yolk sac tumour  ++ - 
Seminoma - ± 
Embryonal carcinoma  ± ± 
Choriocarcinoma  - ++ 
Teratoma ± - 
++ = strongly positive levels; ± = levels may be negative or moderately positive; –
 = negative levels. 
AFP, α-fetoprotein; GCT, germ cell tumour; HCG, human chorionic gonadotrophin. 
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Table 2 | Summary of AFP, HCG and LDH marker levels in the prognostic groups 
of the IGCCC classification (adapted from reference11) 
 
 
Clinical variable 
 
 
Seminoma 
 
NSGCT 
Good-prognosis group   
Primary site Any Testis or retroperitoneal 
Metastases No NPVM No NPVM 
AFP (ng/ml) Normal <1,000 
HCG (IU/L) Any <5,000 
LDH (xULN) Any <1.5 xULN 
Intermediate-prognosis 
group 
  
Primary site Any Testis or retroperitoneal 
Metastases NPVM No NPVM 
AFP (ng/ml) Normal ≥1,000 and ≤10,000* 
HCG (IU/L) Any ≥5,000 and ≤50,000* 
LDH (xULN) Any ≥1.5 and ≤10 xULN* 
Poor-prognosis group   
Primary site  
 
No patients classified as 
poor prognosis 
Mediastinal**; or testis or 
retroperitoneal with any of 
the risk factors below 
Metastases NPVM** 
AFP (ng/ml) >10,000** 
HCG (IU/L) >50,000** 
LDH (xULN) >10 xULN** 
 
* = any one of these risk-factors will classify a NSGCT patient as intermediate-
prognosis;  
** = any one of these risk-factors will classify a NSGCT patient as poor-prognosis.  
 
AFP, α-fetoprotein; GCT, germ cell tumour; HCG, human chorionic gonadotrophin. 
LDH, lactate dehydrogenase; NSGCT, non-seminomatous GCT; NPVM, non-pulmonary 
visceral metastases; ULN, upper limit of normal. 
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Table 3 | Serum microRNA studies in malignant germ cell tumours (GCTs) and important 
practical considerations.  
 
 
 
Author 
(year) 
 
Serum 
volume 
used 
(µl) 
 
 
RNA 
extraction 
method 
 
Test 
microRNAs 
or 
microRNA 
clusters 
quantified 
 
Haemolysis 
Assessment 
 
Non-
human 
exogenous 
spike-in 
RNA 
added 
 
Normalisation 
approach 
 
Comments 
Murray et a. 
(2011)l 63 
400 miRVana 
PARIS kit 
(Ambion) 
miR-371–
373 (n = 3) 
miR-302–
367 (n = 5) 
No No Small RNA 
concentration 
First report of 
utility of serum 
microRNAs in 
GCTs 
Belge et al. 
(2012) 65 
Not 
described 
Not described miR-371–
373 (n = 3) 
 
No No 18S RNA Letter, with 
sparse technical 
details 
Murray and  
Coleman 
(2012)64 
400 miRVana 
PARIS kit 
(Ambion) 
miR-372-
3p (n = 1) 
miR-367-
3p (n = 1) 
No No Small RNA  
concentration 
Suggested 
additional 
specificity of 
using  
miR-367-3p 
Dieckmann 
et al. (2012) 
13 
200 miRNeasy 
mini kit 
(Qiagen) 
miR-
371~373 
(n = 3) 
 
No No 18S RNA Different reverse 
transcription 
step for 18S 
versus 
microRNAs, 
risking technical 
bias  
Gillis et al. 
(2013)66 
50 TaqMan 
miRNA ABC 
purification 
kit; Panel A 
(Life 
Technologies) 
miR-
371~373 
(n = 3) 
miR-
302/367 
(n = 4) 
No Yes; 
cel-miR-
39-3p  
ath-miR-
159a 
miR-20a-5p 
miR-93-5p 
Four serum 
microRNA 
panel* identified 
as most sensitive 
and specific 
Syring et al. 
(2015) 70 
400 miRVana 
PARIS kit 
(Ambion) 
miR-
371~373 
(n = 3) 
miR-
302/367 
(n = 4) 
No Yes;  
cel-miR-
39-3p 
None Four serum 
microRNA 
panel* 
confirmed as 
most sensitive 
and specific 
Spiekermann 
et al. 
(2015)68 
 
200 miRNeasy 
mini kit 
(Qiagen) 
miR-371a-
3p (n = 1) 
No No miR-20a-5p Only single 
microRNA 
tested 
Rijlaarsdam 
et al. (2015) 
67 
50 TaqMan 
miRNA ABC 
purification 
kit; Panels 
A&B 
(Life 
Technologies) 
Global 
profiling 
study 
(n ~750) 
No Yes; 
ath-miR-
159a 
Global 
normalisation 
(PMID 
19531210) 
Appropriate 
normalization 
approach for a 
global profiling 
study used 
 Confirmation of 
the relevance of 
miR-371–373 
microRNAs. 
Spiekermann 
et al. (2015) 
69 
200 miRNeasy 
mini kit 
(Qiagen) 
miR-371–
373 (n = 3) 
 
No No 18S RNA, but 
suggested 
none required  
Different reverse 
transcription 
step for 18S. 
Suggestion that 
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* Four serum microRNA panel comprising miR-371a-3p, miR-372-3p, miR-373-3p and miR-367-3p 
 
normalization ( 
relative 
quantification) 
not required  
Murray et al. 
(2016) 12 
200 miRNeasy 
serum/plasma 
kit (Qiagen) 
miR-371–
373 (n = 3) 
miR-302–
367 (n = 5) 
Yes:  
ΔCt (miR-
23a-3p–
miR-451a) 
Yes: 
cel-miR-
39-3p 
miR-30b-5p Four serum 
microRNA 
panel* 
confirmed.  
First 
demonstration of 
relapse detection 
